Newcastle University

Research Interests

Pharmacogenetic studies on the discovery of novel human genetic polymorphisms, their functional significance and their relationship to outcome of drug therapy, susceptibility to adverse drug reactions and susceptibility to complex diseases.

• Anstee QM, Daly AK, Day CP. Genetic modifiers of non-alcoholic fatty liver disease progression. Biochimica et Biophysica Acta: Molecular Basis of Disease 2011, 1812(11), 1557-1566.
• Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999, 353(9154), 717-719.
• Atkinson A, Singleton AB, Steward A, Ince PG, Perry RH, McKeith IG, Fairbairn AF, Edwardson JA, Daly AK, Morris CM. CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease. Pharmacogenetics and Genomics 1999, 9(1), 31-36.
• Welfare MR, Aitkin M, Bassendine MF, Daly AK. Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: Lack of a polymorphism in CYP1A2 in Caucasians. Pharmacogenetics 1999, 9(3), 367-376.
• Daly AK. Using genome-wide association studies to identify genes important in serious adverse drug reactions. Annual Review of Pharmacology and Toxicology 2012, 52(1), 21-35.
• Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metabolism Reviews 2012, 44(1), 116-126.
• Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, Deloukas P, Daly AK, Park BK, Aarons L, Ogungbenro K, Kamali F, Hughes D, Pirmohamed M. The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. British Journal of Clinical Pharmacology 2012, 73(1), 66-76.
• Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, Ruiz-Cabello F, Donaldson PT, Stephens C, Pirmohamed M, Romero-Gomez M, Navarro JM, Fontana RJ, Miller M, Groome M, Bondon-Guitton E, Conforti A, Stricker BHC, Carvajal A, Ibanez L, Yue Q-Y, Eichelbaum M, Floratos A, Pe'er I, Daly MJ, Goldstein DB, Dillon JF, Nelson MR, Watkins PB, Daly AK. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and class II alleles. Gastroenterology 2011, 141(1), 338-347.
• Biss TT, Avery PJ, Brandao LR, Chalmers EA, Williams MD, Grainger JD, Leathart JB, Hanley JP, Daly AK, Kamali F. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood 2011, 119(3), 868-873.
• Howard R, Leathart JB, French DJ, Krishan E, Kohnke H, Wadelius M, van Schie R, Verhoef T, Maitland van der Zee AH, Daly AK, Barallon R. Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon(R) probes. Clinica Chimica Acta 2011, 412(23-24), 2063-2069.
• Ozhan G, Lochan R, Leathart JB, Charnley R, Daly AK. Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility. Pancreas 2011, 40(8), 1289-1294.
• Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK. Case Definition and Phenotype Standardization in Drug-Induced Liver Injury. Clinical Pharmacology & Therapeutics 2011, 89(6), 806-815.
• Daly AK, Ballestri S, Carulli L, Loria P, Day CP. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology 2011, 5(2), 253-263.
• Valenti L, Nobili V, Al-Serri A, Rametta R, Leathart JB, Zappa MA, Dongiovanni P, Fracanzani AL, Alterio A, Roviaro G, Daly AK, Fargion S, Day CP. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. Journal of Hepatology 2011, 55(6), 1409-1414.
• Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JBS, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP, Daly AK. The SOD2 C₄₇T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. Journal of Hepatology 2012, 56(2), 448-454.
• Anstee QM, Daly AK, Day CP. Genetic modifiers of non-alcoholic fatty liver disease progression. Biochimica et Biophysica Acta: Molecular Basis of Disease 2011, 1812(11), 1557-1566.
• Illingworth NA, Boddy AV, Daly AK, Veal GJ. Characterisation of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. British Journal of Pharmacology 2011, 162(4), 989-999.
• Ballestri S, Day CP, Daly AK. Polymorphism in the Farnesyl Diphosphate Farnesyl Transferase 1 Gene and Nonalcoholic Fatty Liver Disease Severity. Gastroenterology 2011, 140(5), 1694-1695.
• Wahie S, Daly AK, Cordell HJ, Goodfield MJ, Jones SK, Lovell CR, Carmichael AJ, Carr MM, Drummond A, Natarajan S, Smith CH, Reynolds NJ, Meggitt SJ. Clinical and Pharmacogenetic Influences on Response to Hydroxychloroquine in Discoid Lupus Erythematosus: A Retrospective Cohort Study. Journal of Investigative Dermatology 2011, 131(10), 1981-1986.
• Becquement L, Alfrieve A, Amstutz U, Brauch H, Jacqz-Algrain E, Laurent-Puig P, Molina MA, Niemi M, Schwab M, Somogyi AA, Thervet E, Maitland-van der Zee AH, van Kuilenburg ABP, van Schaik RHN, Verstuyft C, Wadelius M, Daly AK. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 2011, 12(1), 113-124.
• Lochan R, Daly AK, Reeves HL, Charnley R. Family history of cancer and tobacco exposure in index cases of pancreatic ductal adenocarcinoma. Journal of Oncology 2011. In Press.
• Anstee QM, Daly AK, Day CP. Genetics of alcoholic liver disease and nonalcoholic fatty liver disease. Seminars in Liver Disease 2011, 31(2), 128-146.
• Al Maruf A, Ahmed MU, Yasmin H, Ullah MA, Azad MAK, Daly AK, Hasnat A. Genotypes and phenotypes of CYP3A in Bangladeshi population. Clinica Chimica Acta 2011, 412(7-8), 531-536.
• Lochan R, Daly AK, Reeves HL, Charnley R. The role of tobacco derived carcinogens in pancreas cancer. ISRN Oncology 2011. In Press.
• Aithal GP, Daly AK. Preempting and preventing drug-induced liver injury. Nature Genetics 2010. New York, NY: Nature Publishing Group, 42(8), 650-651.
• Daly AK. Genome-wide association studies in pharmacogenomics. Nature Reviews: Genetics 2010. , 11(4), 241-246.
• Andrews E, Armstrong M, Tugwood J, Swan D, Glaves P, Pirmohamed M, Aithal GP, Wright MC, Day CP, Daly AK. A Role for the Pregnane X Receptor in Flucloxacillin-Induced Liver Injury. Hepatology 2010, 51(5), 1656-1664.
• Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, Day CP, Aithal GP. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. Journal of Hepatology 2010,53 6 1049-1053.
• Verhoef TI, Redekop WK, Darba J, Geitona M, Hughes DA, Siebert U, de Boer A, van der Zee Maitland AH, Barallon R, Briz M, Daly A, Haschke-Becher E, Kamali F, Kirchheiner J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, van Schie RM, Wadelius M, EU-PACT Group. A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics 2010. , 11(7), 989-1002.
• Potter C, Cordell HJ, Barton A, Daly AK, Hyrich K, Mann D, Morgan A, Wilson AG, Isaacs J. Association between anti-TNF treatment response and genetic variants within the TLR and NFkB signalling pathways. Annals of Rheumatic Diseases 2010, 69(7), 1315-1320.
• Daly AK. Drug-induced liver injury: past, present and future. Pharmacogenomics 2010, 11(5), 607-611.
• Dongiovanni P, Valenti L, Rametta R, Daly A, Nobili V, Mozzi E, Leathart J, Pietrobattista A, Burt A, Maggioni M, Fracanzani A, Lattuada E, Zappa M, Roviaro G, Marchesini G, Day C, Fargion S. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 2010,59 2 267-273.
• Valenti L, Al-Serri A, Daly AK, Galmozzi E, Rametta R, Dongiovanni P, Nobili V, Mozzi E, Roviaro G, Vanni E, Bugianesi E, Maggioni M, Fracanzani AL, Fargion S, Day CP. Homozygosity for the Patatin-Like Phospholipase-3/Adiponutrin I148M Polymorphism Influences Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Hepatology 2010, 51(4), 1209-1217.
• Caple F, Williams EA, Spiers A, Tyson J, Burtle B, Daly AK, Mathers JC, Hesketh JE. Inter-individual variation in DNA damage and base excision repair in young, healthy non-smokers: effects of dietary supplementation and genotype. British Journal of Nutrition 2010, 103(11), 1585-1593.
• Seth D, Daly A, Haber P, Day C. Patatin-like phospholipase domain containing 3: A case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease. Hepatology 2010, 51(4), 1463-1465.
• Daly AK. Pharmacogenetics and human genetic polymorphisms. Biochemical Journal 2010, 429, 435-449.
• Savill SA, Leitch HF, Daly AK, Harvey JN, Thomas TH. Polymorphisms in the Tropomyosin TPM1 Short Isoform Promoter Alter Gene Expression and Are Associated With Increased Risk of Metabolic Syndrome. American Journal of Hypertension 2010, 23(4), 399-404.
• Rowbotham SE, Boddy AV, Redfern CPF, Veal GJ, Daly AK. Relevance of non-synonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug Metabolism and Disposition 2010, 38(8), 1261-1266.
• Rowbotham SE, Illingworth NA, Daly AK, Veal GJ, Boddy AV. Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans. Drug Metabolism and Disposition 2010, 38(7), 1211-1217.
• Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, Graham J, Park BK, Dillon JF, Bernal W, Cordell HJ, Pirmohamed M, Aithal GP, Day CP. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genetics 2009, 41(7), 816-819.
• Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MTM, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA, Chen YT, Wen MS, Caraco Y, Achache I, Blotnick S, Muszkat M, Shin JG, Kim HS, Suarez-Kurtz G, Perini JA, Silva-Assuncao E, Anderson JL, Horne BD, Carlquist JF, Caldwell MD, Berg RL, Burmester JK, Goh BC, Lee SC, Kamali F, Sconce E, Daly AK, Wu AHB, Langaee TY, Feng H, Cavallari L, Momary K, Pirmohamed M, Jorgensen A, Toh CH, Williamson P, McLeod H, Evans JP, Weck KE, Brensinger C, Nakamura Y, Mushiroda T, Veenstra D, Meckley L, Rieder MJ, Rettie AE, Wadelius M, Melhus H, Stein CM, Schwartz U, Kurnik D, Deych E, Lenzini P, Eby C, Chen LY, Deloukas P, Motsinger-Reif A, Sagreiya H, Srinivasan BS, Lantz E, Chang T, Ritchie M, Lu LS, Shin JG, Int Warfarin Pharmacogenetics Cons. Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. New England Journal of Medicine 2009, 360(8), 753-764.
• Jorgensen AL, Al-Zubiedi S, Zhang JE, Keniry A, Hanson A, Hughes DA, van Eker D, Stevens L, Hawkins K, Toh CH, Kamali F, Daly AK, Fitzmaurice D, Coffey A, Williamson PR, Park BK, Deloukas P, Pirmohamed M. Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenetics and Genomics 2009, 19(10), 800-812.
• Daly AK, Day CP. Genetic Association Studies in Drug-Induced Liver Injury. Seminars in Liver Disease 2009. 333 SEVENTH AVE, NEW YORK, NY 10001 USA: THIEME MEDICAL PUBL INC, 29(4), 400-411.
• van Schie RMF, Wadelius M, Kamali F, Daly AK, Manolopoulos VG, de Boer A, Barallon R, Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, Maitland-van eer Zee AH. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009,10 10 1687-1695.
• Tyson J, Caple F, Spiers A, Burtle B, Daly AK, Williams EA, Hesketh JE, Mathers JC. Inter-individual variation in nucleotide excision repair in young adults: effects of age, adiposity, micronutrient supplementation and genotype. British Journal of Nutrition 2009, 101(9), 1316-1323.
• Andrews EAG, Daly AK. Flucloxacillin-induced liver injury. Toxicology 2008. , 254(3), 158-163.
• Thanacoody RHK, Daly AK, Reilly JG, Ferrier IN, Thomas SHL. Factors affecting drug concentrations and QT interval during thioridazine therapy. Clinical Pharmacology and Therapeutics 2007, 82(5), 555-565.
• Daly AK, Aithal GP, Leathart JBS, Swainsbury RA, Dang TS, Day CP. Genetic Susceptibility to Diclofenac-Induced Hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 Genotypes. Gastroenterology 2007, 132(1), 272-281.
• Daly AK. Individualized drug therapy. Current Opinion in Drug Discovery and Development 2007, 10(1), 29-36.
• Mutch E, Daly AK, Williams FM. The Relationship between PON1 Phenotype and PON1-192 Genotype in Detoxification of Three Oxons by Human Liver. Drug Metabolism and Disposition 2007, 35(2), 315-320.
• Hatch E, Sconce EA, Daly AK, Kamali F. A rapid genotyping method for the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene. Journal of Thrombosis and Haemostasis 2006, 4(5), 1158-1159.
• Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F. APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenetics and Genomics 2006, 16(8), 609-611.
• Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clinical Pharmacokinetics 2006. , 45(1), 13-31.
• Todhunter CE, Sutherland-Craggs A, Bartram S, Donaldson PT, Daly AK, Francis RM, Mansfield JC, Thompson NP. Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease. Gut 2005, 54(11), 1579-1584.
• Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT, Neuvonen PJ. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clinical Pharmacology and Therapeutics 2005,77 6 468-478.
• Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen. Blood 2005, 106(7), 2329-2333.
• Kamali F, Khan TI, King BP, Frearson R, Kesteven P, Wood P, Daly AK, Wynne H. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clinical Pharmacology and Therapeutics 2004,75 3 204-212.
• Anglicheau D, Thervet E, Etienne I, De Ligny BH, Le Meur Y, Touchard G, Buchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. CLINICAL PHARMACOLOGY & THERAPEUTICS 2004,75 5 422-433.
• Daly AK. Development of analytical technology in pharmacogenetic research. Naunyn-Schmiedeberg's Archives of Pharmacology 2004. ,369 1 133-140.
• Aithal GP, Ramsay L, Daly AK, Sonchit N, Leathart JBS, Alexander G, Kenna JG, Caldwell J, Day CP. Hepatic Adducts, Circulating Antibodies, and Cytokine Polymorphisms in Patients with Diclofenac Hepatotoxicity. Hepatology 2004,39 5 1430-1440.
• Kocabas NA, Sardas S, Cholerton S, Daly AK, Karakaya AE. N-Acetyltransferase (NAT2) Polymorphism and Breast Cancer Susceptibility: A Lack of Association in a Case-Control Study of Turkish Population. International Journal of Toxicology 2004,23 1 25-31.
• Daly AK. Pharmacogenetics of the cytochromes P450. Current Topics in Medicinal Chemistry 2004. ,4 16 1733-1744.
• King BP, Khan TI, Aithal GP, Kamali F, Daly AK. Upstream and coding region CYP2C9 polymorphisms: Correlation with warfarin dose and metabolism. Pharmacogenetics 2004,14 12 813-822.
• Malhi H, Atac B, Daly AK, Gupta S. Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. Postgraduate Medical Journal 2004,80 940 107-109.
• Dunn SA, Mohteshamzadeh M, Daly AK, Thomas TH. Altered tropomyosin expression in essential hypertension. Hypertension 2003,41 2 347-354.
• Daly AK. Candidate gene case-control studies. Pharmacogenomics 2003. ,4 2 127-139.
• King BP, Leathart JBS, Mutch E, Williams FM, Daly AK. CYP3A5 phenotype-genotype correlations in a British population. British Journal of Clinical Pharmacology 2003,55 6 625-629.
• Mutch E, Daly AK, Leathart JBS, Blain PG, Williams FM. Do multiple cytochrome P450 isoforms contribute to parathion metabolism in man?. Archives of Toxicology 2003, 77(6), 313-320.
• Vidali M, Stewart SF, Rolla R, Daly AK, Chen Y, Mottaran E, Jones DEJ, Leathart JB, Day CP, Albano E. Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. Hepatology 2003,37 2 410-419.
• Thervet E, Anglicheau D, King B, Schlageter M-H, Cassinat B, Beaune P, Legendre C, Daly AK. Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003,76 8 1233-1235.
• Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003. ,13 5 247-252.
• Daly AK. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundamental and Clinical Pharmacology 2003. ,17 1 27-41.
• Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clinical Pharmacology and Therapeutics 2003,74 4 380-387.
• Khan T, Kamali F, Daly A, King B, Wynne HA. Warfarin sensitivity: Be aware of genetic influence. Age and Ageing 2003,32 2 226-227.
• Sutherland-Craggs A, Mansfield JC, Hudson M, Cuthbert A, Fisher S, Mathew C, Bartram S, Daly A, Francis R, Thompson NP. [abstract] Osteoporosis in Crohn's disease is not determined by NOD2 genotype. Gut 2002, 50(s2), A80 abstract no. 291.
• Aithal GP, Leathart JB, Dang TS, Day CP, Daly AK. Association of udp-glucuronosyltransferase (UGT) 2B7 genotype with diclofenac-induced hepatotoxicity. In: Hepatology: 53rd Annual Meeting of the Association for the Study of Liver Diseases. 2002, Boston, Massachusetts, USA: John Wiley & Sons, Inc.
• Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002, 12(2), 121-132.
• Bahadur N, Leathart JBS, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, Houdt JV, Hendrickx J, Mannens G, Bohets H, Williams FM, Armstrong M, Crespi CL, Daly AK. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochemical Pharmacology 2002,64 11 1579-1589.
• Daly AK, Day CP, Aithal GP. CYP2C9 polymorphism and warfarin dose requirements. British Journal of Clinical Pharmacology 2002, 53(4), 408-409.
• Gilhooly TC, Daly AK. CYP2D6 deficiency, a factor in ecstasy related deaths?. British Journal of Clinical Pharmacology 2002, 54(1), 69-70.
• Kocabas NA, Sardas S, Cholerton S, Daly AK, Karakaya AS. Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. Archives of Toxicology 2002, 76(11), 643-649.
• Day C, Leathart J, Daly A. Genetic evidence that fatty liver is involved in the pathogenesis of advanced alcoholic liver disease. Journal of Hepatology 2002, 36(s1), 16 abstract no. 41.
• Daly AK, Day CP, Donaldson PT. Polymorphisms in immunoregulatory genes: towards individualised immunosupressive therapy?. American Journal of PharmacoGenomics 2002, 2(1), 13-23.
• Stewart SF, Leathart JB, Chen Y, Daly AK, Rolla R, Vay D, Mottaran E, Vidali M, Albano E, Day CP. Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. Hepatology 2002, 36(6), 1355-1360.
• Aithal GP, Day CP, Leathart JBS, Daly AK, Hudson M. Association of a 5'-flanking region polymorphism in the interleukin-4 gene with Crohn’s disease in a British population.. Genes and Immunity 2001, 2, 44-47.
• Aithal GP, Day CP, Leathart J, Daly AK, Hudson M. Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn's disease in a British population. Genes and Immunity 2001, 2(1), 44-47.
• Daly AK and Day CP. Candidate gene case-control association studies: advantages and potential pitfalls.. British Journal of Clinical Pharmacology 2001, 52, 489-499.
• Løvlie R, Daly AK, Molven A, Steen VM. CYP2D polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?. Pharmacogenetics 2001, 11, 45-56.
• Ingelman-Sundberg M, Oscarson M, Daly AK, Garte S and Nebert DW. Human cytochrome P-450 (CYP) genes: A web page for the nomenclature of alleles.. Cancer Epidemiology Biomarkers & Prevention 2001, 10, 1307-1308.
• Daly AK, Hall AG. Pharmacogenetics of cytotoxic drugs. Expert Review of Anticancer Therapy 2001. , 1(2), 301-308.
• Harbottle A, Daly AK, Atherton K, Campbell FC. Role of glutathione S-transferase P1, p-glycoprotein and multidrug resistance associated protein 1 in acquired doxorubicin resistance.. Int J Cancer 2001, 92, 777-783.
• Aithal GP, Craggs A, Day CP, Welfare M, Daly AK, Mansfield JC, Hudson M. Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease. Digestive Diseases and Sciences 2001, 46(7), 1520-1525.
• Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics 2001, 27(4), 383-391.
• Zhang J, Kuehl P, Green ED, Touchman JW, Watkins P, Daly AK, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Wrighton SA, Hancock M, Kim R, Strom S, Thummel K, Russell CG, Hudson JR, Schuetz EG and Boguski MS. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants.. Pharmacogenetics 2001, 11, 555-572..
• Ford GA, Wood SM, Daly AK. CYP2D6 and CYP2C19 genotypes of patients with terodilin cardiotoxicity identified through the yellow card system. British Journal of Clinical Pharmacology 2000, 50(1), 77-80.
• Ford GA, Wood SM, Daly A. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. British Journal of Clinical Pharmacology 2000, 50(1), 77-80.
• Lovlie R, Daly AK, Blennerhassett R, Ferrier N, Steen VM. Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. International Journal of Neuropsychopharmacology 2000, 3(1), 61-65.
• Ingelman-Sundberg M, Daly AK, Oscarson M, Nebert DW. Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. Pharmacogenetics 2000, 10(1), 91-93.
• McSorley LC, Daly AK. Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochemical Pharmacology 2000, 60(4), 517-526.
• Grove J, Daly AK, Bassendine MF, Gilvarry E, Day CP. Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 2000, 46(4), 540-545.
• London SJ, Smart J, Daly AK. Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. Lung Cancer 2000, 28(2), 147-155.
• Agarwal K, Daly AK, Leathart JB, Hudson M, Day CP. Polymorphisms of immunoregulatory genes: A step towards individually tailored immunosuppression?. In: British Association for the Study of the Liver Meeting. 2001, University of Southampton: BMJ Publishing Group Ltd.
• Brown MA, Edwards S, Hoyle E, Campbell S, Laval S, Daly AK, Pile KD, Calin A, Ebringer A, Weeks DE, Wordsworth BP. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Human Molecular Genetics 2000, 9(11), 1563-1566.
• Aithal GP, Day CP, Leathart JBS, Daly AK. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000, 10(6), 511-518.
• Stewart SF, Daly AK, Chen YN, Leathart JB, Rolla R, Vay D, Mottaran E, Vidali M, Albano E, Day CP. Susceptibility to alcoholic liver disease is due to genetically determined differences in the immune response to acetaldehyde adducts. In: HEPATOLOGY. 2000.
• Welfare MR, Bassendine MF, Daly AK. The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects. British Journal of Clinical Pharmacology 2000, 49(3), 240-243.
• Smart J, Daly AK. Variation in induced CYP1A1 levels: Relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics 2000, 10(1), 11-24.
• D. W. Nebert, M. Ingelman-Sundberg and A. K. Daly. Genetic epidemiology of environmental toxicity and cancer susceptibility: Human allelic polymorphisms in drug- metabolizing enzyme genes, their functional importance, and nomenclature issues. Drug Metabolism Reviews 1999, 31, 467-487.
• S. J. London, J. R. Idle, A. K. Daly and G. A. Coetzee. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 1999, 353, 898-899.
• G. F. Chen, Y. M. Tang, B. Green, D. X. Lin, F. P. Guengerich, A. K. Daly, N. E. Caporaso and F. F. Kadlubar. Low frequency of CYP2A6 gene polymorphism as revealed by a one- step polymerase chain reaction method. Pharmacogenetics 1999, 9, 327-332.
• M. Welfare, A. M. Adeokun, M. F. Bassendine and A. K. Daly. Polymorphisms in GSTP1, GSTM1, and GSTT1 and susceptibility to colorectal cancer. Cancer Epidemiology Biomarkers & Prevention 1999, 8, 289-292.
• Yule, S. M., Walker, D., Cole, M., McSorley, L., Cholerton, S., Daly, A. K., Pearson, A. D. J., Boddy, A. V. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metabolism and Disposition 1999, 27(3), 417-421.
• Jones DEJ, Watt FE, Grove J, Newton JL, Daly AK, Gregory WL, Day CP, James OFW, Bassendine MF. Tumour necrosis factor-α promoter polymorphisms in primary biliary cirrhosis. Journal of Hepatology 1999,30 2 232-236.
• G. P. Aithal, C. P. Day, P. J. L. Kesteven and A. K. Daly. Warfarin dose requirement and CYP2C9 polymorphisms - Reply. Lancet 1999, 353, 1972-1973.
• G. C. Ibeanu, J. Blaisdell, B. I. Ghanayem, C. Beyeler, S. Benhamou, C. Bouchardy, G. R. Wilkinson, P. Dayer, A. K. Daly and J. A. Goldstein. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998, 8, 129-135.
• J. B. S. Leathart, S. J. London, A. Steward, J. D. Adams, J. R. Idle and A. K. Daly. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 1998, 8, 529-541.
• K. S. Fairbrother, J. Grove, I. de Waziers, D. T. Steimel, C. P. Day, C. L. Crespi and A. K. Daly. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 1998, 8, 543-552.
• J. Grove, A. K. Daly, A. D. Burt, M. Guzail, M. F. Bassendine and C. P. Day. Do HLA-H mutations influence liver iron content or disease risk in alcoholics?. Gut 1998, 43, 153-154.
• Smith BC, Grove J, Guzail MA, Day CP, Daly AK, Burt AD, Bassendine MF. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998,27 6 1695-1699.
• J. Grove, A. K. Daly, A. D. Burt, M. Guzail, O. F. W. James, M. F. Bassendine and C. P. Day. Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut 1998, 43, 262-266.
• F. Zappala, J. Grove, F. E. Watt, A. K. Daly, C. P. Day, M. F. Bassendine and D. E. J. Jones. No evidence for involvement of the interleukin-10 -592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. Journal of Hepatology 1998, 28, 820-823.
• A. K. Daly, K. S. Fairbrother and J. Smart. Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. Toxicology Letters 1998, 103, 143-147.
• Grove J, Brown AStJM, Daly AK, Bassendine MF, James OFW, Day CP. The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: Effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics 1998,8 4 335-342.
• C. P. Day, J. Grove, A. K. Daly, M. W. Stewart, P. J. Avery and M. Walker. Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia 1998, 41, 430-434.
• M. Armstrong, A. K. Daly, R. Blennerhassett, N. Ferrier and J. R. Idle. Antipsychotic drug-Induced movement disorders in schizophrenics in relation to CYP2D6 genotype. British Journal of Psychiatry 1997, 170, 23-26.
• R. Lovlie, A. K. Daly, J. R. Idle and V. M. Steen. Characterization of the 16+9 kb and 30+9 kb CYP2D6 XbaI haplotypes. Pharmacogenetics 1997, 7, 149-152.
• Hildesheim A., Anderson L.M., Chen C.J., Cheng Y.J., Brinton L.A., Daly A.K., Reed C.D., Chen I.H., Caporaso N.E., Hsu M.M., Chen J.Y., Idle J.R., Hoover R.N., Yang C.S. and Chhabra S.K. CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 1997, 89, 1207-1212.
• S. J. London, A. K. Daly, J. B. S. Leathart, W. C. Navidi, C. C. Carpenter and J. R. Idle. Genetic polymorphism of CYP2D6 and lung cancer risk in African- Americans and Caucasians in Los Angeles county. Carcinogenesis 1997, 18, 1203-1214.
• S. J. London, T. SullivanKlose, A. K. Daly and J. R. Idle. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics 1997, 7, 401-404.
• Singleton A.B., Atkinson A.M., Gibson A.M., Daly A., Morris C.M. No association between PS-2 polymorphism and AD. Lancet 1997, 350, 336-337.
• A. B. Singleton, A. M. Gibson, A. L. Atkinson, A. Daly and C. M. Morris. Presenilin polymorphisms in Alzheimer's disease. Lancet 1997, 350, 958-959.
• M. R. Welfare, J. Cooper, M. F. Bassendine and A. K. Daly. Relationship between acetylator status, smoking, diet and colorectal cancer risk in the north-east of England. Carcinogenesis 1997, 18, 1351-1354.
• A. K. Daly, K. S. Fairbrother, O. A. Andreassen, S. J. London, J. R. Idle and V. M. Steen. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotypes. Pharmacogenetics 1996, 6, 319-328.
• M. S. Sandy, M. Armstrong, C. M. Tanner, A. K. Daly, D. A. DiMonte, J. W. Langston and J. R. Idle. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Neurology 1996, 47, 225-230.
• A. K. Daly, V. M. Steen, K. S. Fairbrother and J. R. Idle. CYP2D6 multiallelism. Cytochrome P450, Pt B 1996, 272, 199-210.
• S. J. London, A. K. Daly, J. B. S. Leathart, W. C. Navidi and J. R. Idle. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics 1996, 6, 527-533.
• London SJ, Daly AK, Cooper J, Carpenter CL, Navidi WC, Ding L, Idle JR. Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymorphism among African-Americans and Caucasians in Los Angeles County. Pharmacogenetics 1996,6 2 151-158.
• A. K. Daly, J. Brockmoller, F. Broly, M. Eichelbaum, W. E. Evans, F. J. Gonzalez, J. D. Huang, J. R. Idle, M. IngelmanSundberg, T. Ishizaki, E. JacqzAigrain, U. A. Meyer, D. W. Nebert, V. M. Steen, C. R. Wolf and U. M. Zanger. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996, 6, 193-201.
• C. Beyeler, M. Armstrong, H. A. Bird, J. R. Idle and A. K. Daly. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Annals of the Rheumatic Diseases 1996, 55, 66-68.
• K. HartiganGo, D. N. Bateman, A. K. Daly and S. H. L. Thomas. Stereoselective cardiotoxic effects of terodiline. Clinical Pharmacology & Therapeutics 1996, 60, 89-98.
• R. Lovlie, A. K. Daly, A. Molven, J. R. Idle and V. M. Steen. Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. Febs Letters 1996, 392, 30-34.
• Walker, D., Flinois, J. P., Monkman, S. C., Beloc, C., Boddy, A. V., Cholerton, S., Daly, A. K., Lind, M. J., Pearson, A. D. J., Beaune, P. H., Idle, J. R. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochemical Pharmocology 1994, 47(7), 1157-1163.
• Idle, J. R., Armstrong, M., Boddy, A. V., Boustead, C., Cholerton, S., Cooper, J., Daly, A. K., Ellis, J., Gregory, W., Hadidi, H., Hofer, C., Holt, J., Leathart, J., McCracken, N., Monkman, S. C., Painter, J. E., Taber, H., Walker, D., Yule, M. The pharmacogenetics of chemical carcinogenesis. Pharmacogenetics 1992, 2(6), 246-258.
• Redfern CPF, Daly AK. Cellular retinoic acid-binding protein from neonatal rat skin: Purification and analysis. Methods in Enzymology 1990, 189, 307-314.
• Daly AK, Redfern CPF, Martin B. Identification and analysis of retinoic acid-binding proteins and receptors from nuclei of mammalican cells. Methods in Enzymology 1990, 189, 239-247.
• Redfern CPF, Daly AK, Latham JAE, Todd C. The biological activity of retinoids in melanoma cells: Induction of expression of retinoic acid receptor-β by retinoic acid in S91 melanoma cells. FEBS Letters 1990, 273(1-2), 19-22.
• Rees JL, Daly AK, Redfern CPF. Differential expression of the alpha and beta retinoic acid receptors in tissues of the rat. Biochemical Journal 1989, 259(3), 917-919.
• Daly AK, Rees JL, Redfern CPF. Nuclear retinoic acid binding proteins and receptors in retinoic acid responsive cell lines. Experimental Cell Biology 1989, 57(6), 339-345.
• Daly, A.K., Redfern, C.P.F. Purification and properties of cellular retinois acid-binding protein from neonatal rat skin. Biochimica et Biophysica Acta 1988, 965(2-3), 118-126.
• Daly AK, Redfern CPF. Characterisation of a retinoic-acid-binding component from F9 embryonal-carcinoma-cell nuclei. European Journal of Biochemistry 1987, 168(1), 133-139.